Most of the current treatment strategies focus on administrating exogenous agonists or analogues (GLP1 in schizophrenia, visceral pain hypersensitivity, and depression) and receptor antagonist (serotonin in visceral pain) of these molecules. Here, GLP1R is linked to schizophrenia.